查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018525

僵直性脊椎炎市場：2026-2032年全球市場預測（依給藥途徑、病患年齡層、最終使用者和給藥途徑分類）

Ankylosing Spondylitis Market by Administration Route, Patient Age Group, End User, Route Of Administration - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，僵直性脊椎炎市場價值將達到 60.4 億美元，到 2026 年將成長至 65.1 億美元，到 2032 年將達到 108.1 億美元，年複合成長率為 8.67%。

主要市場統計數據
基準年 2025 60.4億美元
預計年份：2026年 65.1億美元
預測年份 2032 108.1億美元
複合年成長率 (%) 8.67%

這為僵直性脊椎炎提供了一個全面的臨床和系統框架，指導相關人員考慮採用綜合方法進行治療和護理。

僵直性脊椎炎是一種複雜的發炎性疾病，涉及風濕病學、整形外科、復健醫學和衛生經濟學等多個領域。本報告的引言部分概述了僵直性脊椎炎的臨床特徵、不斷發展的治療方法，以及影響相關人員如何進行診斷、治療和長期管理的支付方和醫療服務動態的轉變。透過對近期發病機制研究成果和實用治療路徑的探討，本報告為臨床醫生、保險公司、製藥公司和患者權益倡導組織制定策略決策提供了依據。

治療、診斷和醫療保健服務體系重組的創新，如何共同重塑整個僵直性脊椎炎生態系統的臨床實踐、證據需求和支付方期望？

在治療創新、診斷技術進步和新型護理模式的推動下，僵直性脊椎炎的治療和照護正經歷著一場意義深遠的變革。新型標靶治療和口服小分子藥物的出現，拓展了生物製藥以外的治療選擇；影像學和生物標記的進步，使得早期診斷更加精準成為可能。這些變革正在重塑臨床診療流程，並提高了人們對疾病持續控制、功能維持和減輕合併症負擔的期望。

關稅政策變化對僵直性脊椎炎治療供應鏈、籌資策略和商業性韌性的實際影響

2025年關稅政策轉變的累積影響，為整個生物製藥價值鏈的供應鏈設計、籌資策略和定價結構帶來了新的考量。進口關稅的提高和關稅體系的複雜性凸顯了在地化生產選址決策和分銷網路柔軟性的重要性。製造商和經銷商現在必須仔細權衡集中化生產的效率與區域或國內生產能力帶來的成本節約效益之間的利弊。

將給藥途徑、年齡層和最終用戶環境與臨床治療途徑和商業性重點聯繫起來的高解析度分割分析。

在僵直性脊椎炎領域，不同細分市場層面的細微差異是影響臨床應用、患者體驗和商業化策略的關鍵因素。根據給藥途徑，市場細分為注射劑、靜脈注射和口服劑型，並進行深入研究。注射劑型進一步細分為靜脈輸注和皮下注射，口服劑型進一步細分為膠囊和錠劑。這種觀點闡明了給藥途徑如何影響患者的用藥依從性、臨床監測需求以及臨床實踐的經濟效益。具體而言，研究顯示皮下注射劑型便於門診患者使用，而靜脈注射劑型則主要集中於輸注環境。

針對美洲、歐洲、中東和非洲以及亞太地區不同的還款方案、供應鏈限制和部署模式，制定區域策略。

由於全球主要地區的臨床實踐、報銷框架和供應鏈實際情況差異顯著，區域趨勢仍然是策略規劃的核心。在美洲，人們仍然高度重視基於價值的合約和整合式醫療路徑，並且正在實施先進的支付方流程，以促進收集持續的治療結果和真實世界數據（REW）。相較之下，歐洲、中東和非洲（EMEA）的報銷和監管環境各不相同，更傾向於採用區域性准入策略和合作定價安排。在亞太地區，雖然一些市場的新治療方法正在迅速獲得認可，但其他市場則面臨成本限制，這使得市場准入和業務擴張需要考慮許多因素。

透過證據產生、在地化生產和綜合患者支持來建立競爭優勢的企業策略和夥伴關係模式。

僵直性脊椎炎領域的競爭格局日益呈現出整合式醫療服務模式的特徵，這種模式融合了治療效果、病患支持服務和數據驅動的證據產生。成熟的生物製藥公司持續投資於標靶研發管線和透過拓展適應症實現臨床差異化，而高度專業化的生物技術公司則專注於作用機制創新和市場定位。同時，口服小分子藥物和學名藥生產商正利用製劑改進和差異化給藥系統來搶佔治療領域的各個細分市場。

一套實用的策略手冊，旨在協調證據產生、價值鏈柔軟性和以患者為中心的交付，以實現治療和商業性價值。

產業領導企業應優先採取一系列切實可行的步驟，以協調臨床差異化、商業性可行性和營運韌性。首先，投資於整合證據計劃，將隨機試驗、可操作的真實世界研究和患者報告結果相結合，以向支付者和臨床醫生證明其長期價值。其次，重新配置供應鏈，以平衡集中效率和區域靈活性，並能夠快速應對關稅變化和不斷變化的採購環境。第三，設計以病人為中心的醫療服務模式，考慮給藥途徑偏好和醫療服務地點的經濟因素，以支持藥物依從性和成本效益。

採用透明、多方面的研究途徑，結合一手訪談、二手文獻整合和三角測量分析，以確保獲得可靠的策略見解。

本報告的調查方法結合了質性研究、嚴謹的二手資訊分析和結構化資料整合，以確保研究結果的可重複性和可操作性。主要研究包括對臨床醫生、醫療保險報銷專家、供應鏈高管和患者權益組織代表進行深入訪談，以收集有關臨床實踐中護理模式、就醫障礙和治療偏好的實際見解。這些訪談旨在揭示操作層面的細微差別，並檢驗以假設主導的分析框架。

整合臨床、商業性和營運方面的挑戰，領導者必須解決這些挑戰，才能將治療的進步轉化為病患和系統層面的永續價值。

總之，僵直性脊椎炎的現狀呈現出臨床創新、不斷演進的照護模式和營運壓力並存的特點，這些因素共同為相關人員帶來了機會和挑戰。治療方法的多樣化、診斷技術的進步以及數位醫療的整合正在改變患者的診斷和管理方式，而支付方和採購趨勢則要求更精細的價值溝通和更靈活的供應策略。給藥途徑、患者族群特徵和護理環境之間的相互作用進一步闡明了治療在何處以及如何產生顯著的臨床效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：僵直性脊椎炎市場（依給藥途徑分類）

  • 注射藥物
    • 靜脈注射
    • 皮下注射
  • 靜脈
  • 口服
    • 膠囊
    • 藥片

第9章：僵直性脊椎炎患者年齡層市場

  • 成人版
  • 老年人
  • 兒童

第10章：僵直性脊椎炎市場：依最終用戶分類

  • 居家照護中心
  • 醫院
  • 專科診所

第11章僵直性脊椎炎市場：依給藥途徑分類

  • 注射藥物
    • 靜脈注射
    • 皮下注射
  • 口服
    • 解決方案
    • 藥片
  • 外用
    • 奶油
    • 凝膠

第12章僵直性脊椎炎市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章僵直性脊椎炎市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章僵直性脊椎炎市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 美國僵直性脊椎炎市場

第16章 中國僵直性脊椎炎市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Biothera Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celltrion Healthcare Co.,Ltd.
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hetero Drugs Limited
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Reliance Life Sciences
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Shanghai Pharmaceuticals Holding Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Trinity Biotech PLC
  • UCB, Inc.
  • Xian Janssen Pharmaceutical Ltd
Product Code: MRR-A339DAEFAA9A

The Ankylosing Spondylitis Market was valued at USD 6.04 billion in 2025 and is projected to grow to USD 6.51 billion in 2026, with a CAGR of 8.67%, reaching USD 10.81 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.04 billion
Estimated Year [2026] USD 6.51 billion
Forecast Year [2032] USD 10.81 billion
CAGR (%) 8.67%

Comprehensive clinical and systemic framing of ankylosing spondylitis to orient stakeholders toward integrated therapeutic and care-delivery considerations

Ankylosing spondylitis remains a complex inflammatory condition with implications across rheumatology, orthopedics, rehabilitation, and health economics. This report's opening synthesis frames the clinical profile, evolving therapeutic approaches, and the shifting payer and care-delivery dynamics that shape how stakeholders approach diagnosis, treatment, and long-term management. By situating recent mechanistic discoveries alongside pragmatic treatment pathways, the introduction sets a foundation for strategic decisions by clinicians, payers, manufacturers, and patient advocates.

The narrative emphasizes diagnostic challenges, the heterogeneity of clinical presentation, and the downstream effects on quality of life and functional outcomes. It also foregrounds the interplay between novel biologics, small molecules, and supportive care modalities, highlighting how therapeutic selection increasingly depends on patient comorbidities and route-of-administration considerations. Furthermore, the introduction underscores the role of digital health tools and patient-reported outcomes in driving more personalized care and in supporting value-based contracting discussions. Transitioning from clinical context to commercial implications, this section prepares readers for deeper analysis of policy, regional dynamics, and segment-level insights that follow in subsequent chapters.

How therapeutic innovation, diagnostics, and care-delivery redesign are jointly reshaping clinical practice, evidence needs, and payer expectations across the ankylosing spondylitis ecosystem

The treatment and care landscape for ankylosing spondylitis is undergoing a period of substantive transformation driven by therapeutic innovation, enhanced diagnostics, and new care models. Emerging targeted agents and oral small molecules are expanding the armamentarium beyond traditional biologic classes, while advances in imaging and biomarkers are enabling earlier and more precise diagnosis. These shifts are altering clinical algorithms and increasing expectations for sustained disease control, functional preservation, and reduced comorbidity burden.

Concurrently, payer models and contracting approaches are evolving to reward outcomes and adherence, prompting manufacturers to rethink evidence generation and patient-support infrastructures. Digital therapeutics and remote monitoring tools are gaining traction, creating opportunities for long-term engagement and adherence support but also placing new demands on interoperability and data governance. As a result, successful stakeholders are those aligning clinical value propositions with pragmatic delivery models, investing in real-world evidence generation, and designing differentiated patient access programs. This chapter explores how these transformative currents intersect, and it outlines the strategic implications for clinical development, commercialization, and health-system integration.

Practical implications of tariff policy changes on supply chains, procurement strategies, and commercial resilience for ankylosing spondylitis therapies

The cumulative effects of tariff policy shifts in 2025 introduced new considerations for supply chain design, procurement strategies, and pricing architecture across the biopharmaceutical value chain. Increased import duties and tariff complexity have elevated the importance of local manufacturing footprint decisions and the flexibility of distribution networks. Manufacturers and distributors must now weigh the trade-offs between centralized production efficiencies and the cost mitigation benefits of regional or in-country production capabilities.

These policy developments have implications beyond immediate landed cost adjustments. They affect contractual negotiations with health systems and payers, as procurement teams integrate tariff-related cost variability into sourcing decisions. In parallel, companies are accelerating contingency planning to preserve margin stability and continuity of supply, including strategic stockpiling, multi-sourcing, and selective regionalization of high-volume product lines. Regulatory compliance and customs agility have become competitive differentiators, underscoring the need for cross-functional coordination between commercial, supply chain, and legal teams. Moving forward, stakeholders that proactively model tariff exposure and embed flexible manufacturing and distribution options into their commercial playbooks will be better positioned to sustain market access and operational resilience.

High-resolution segmentation analysis linking administration route, age cohorts, and end-user settings to real-world treatment pathways and commercial priorities

Segment-level nuance is a critical determinant of clinical adoption, patient experience, and commercialization strategy in ankylosing spondylitis. Based on Administration Route, market is studied across Injectable, Intravenous, and Oral. The Injectable is further studied across Intravenous Infusion and Subcutaneous Injection. The Oral is further studied across Capsules and Tablets. This perspective clarifies how route of administration influences adherence patterns, clinical monitoring needs, and site-of-care economics, with subcutaneous formulations offering outpatient convenience and intravenous options concentrated in infusion settings.

Patient heterogeneity also shapes demand and care pathways; based on Patient Age Group, market is studied across Adult, Geriatric, and Pediatric. Age-related differences affect comorbidity profiles, safety considerations, and shared decision-making priorities, thereby informing label strategies and pharmacoepidemiology plans. End-user dynamics determine where care is delivered and how support services are structured: based on End User, market is studied across Homecare Centers, Hospitals, and Specialty Clinics. Each setting has distinct reimbursement, staffing, and monitoring capabilities that influence product positioning and services design.

Finally, route-specific segmentation is further refined: based on Route Of Administration, market is studied across Injectable, Oral, and Topical. The Injectable is further studied across Intravenous Infusion and Subcutaneous Injection. The Oral is further studied across Solutions and Tablets. The Topical is further studied across Creams and Gels. This granular framework helps clarify R&D prioritization, pricing strategy, and patient support program design by aligning formulation choices with real-world use patterns and site-of-care realities.

Regionally calibrated strategies to reconcile divergent reimbursement systems, supply-chain constraints, and adoption patterns across the Americas, EMEA, and Asia-Pacific

Regional dynamics remain central to strategic planning, as clinical practice, reimbursement frameworks, and supply-chain realities vary significantly across major world regions. The Americas continue to demonstrate a strong emphasis on value-based contracting and integrated care pathways, with advanced payer processes that incentivize durable outcomes and real-world evidence collection. In contrast, Europe, Middle East & Africa show heterogeneous reimbursement landscapes and regulatory approaches that favor region-specific access strategies and collaborative pricing arrangements. Asia-Pacific presents rapid uptake of new modalities in some markets alongside cost-constrained environments in others, creating a diverse set of market-entry and scale-up considerations.

These geographic differences affect go-to-market sequencing, evidence-generation priorities, and partner selection. In many cases, early commercial focus on specific high-value submarkets enables proof points that can be adapted for broader regional rollout. Moreover, local manufacturing, regulatory harmonization efforts, and distribution partnerships play pivotal roles in mitigating tariff and logistic exposure across these regions. Accordingly, a regionally calibrated approach that balances uniformity of clinical value messaging with localized operational tactics will be essential for sustained access and uptake across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Corporate strategies and partnership models that are defining competitive advantage through evidence generation, localized manufacturing, and integrated patient support

Competitive dynamics in ankylosing spondylitis are increasingly defined by integrated offerings that combine therapeutic efficacy with patient support services and data-driven evidence generation. Established biopharmaceutical firms continue to invest in clinical differentiation through targeted pipeline assets and extended indication development, while specialty biotech companies focus on mechanistic innovation and niche positioning. Concurrently, manufacturers of oral small molecules and generics are leveraging formulation improvements and differentiated delivery systems to capture segments of the treatment continuum.

Partnerships across the ecosystem are accelerating, with collaborations between pharma companies and specialty service providers enabling bundled solutions that address adherence, monitoring, and outcomes measurement. Diagnostics and imaging firms are deepening engagement with clinical stakeholders to support earlier detection and longitudinal disease management, and contract manufacturing organizations are adapting to demand for more localized production capacity. Collectively, these company-level trends point toward a landscape where strategic alliances, flexible manufacturing models, and robust real-world evidence capabilities determine who can deliver sustained clinical and commercial value.

Actionable strategic playbook for aligning evidence generation, supply-chain flexibility, and patient-centric delivery to capture therapeutic and commercial value

Industry leaders should prioritize a set of actionable measures that align clinical differentiation with commercial viability and operational resilience. First, invest in integrated evidence plans that combine randomized trials, pragmatic real-world studies, and patient-reported outcomes to substantiate long-term value for payers and clinicians. Second, reassess supply-chain footprints to balance centralized efficiencies with regional agility, enabling responsiveness to tariff shifts and procurement variability. Third, design patient-centric delivery models that account for administration-route preferences and site-of-care economics, supporting both adherence and cost-effectiveness.

In addition, cultivate strategic partnerships across diagnostics, digital health, and specialty care networks to accelerate early diagnosis and continuous disease monitoring. Embed flexible contracting options and risk-sharing arrangements tailored to regional reimbursement realities to facilitate market access and reduce payer resistance. Finally, prioritize capability-building in data analytics and regulatory affairs to translate real-world insights into label expansions and differentiated reimbursement conversations. Collectively, these actions will enable organizations to convert clinical innovation into sustainable, patient-centered commercial outcomes.

Transparent, multi-method research approach combining primary interviews, secondary literature synthesis, and triangulated analysis to ensure credible strategic insights

The research methodology underpinning this report combines primary qualitative inquiry with rigorous secondary intelligence and structured data synthesis to ensure reproducibility and actionable clarity. Primary research involved in-depth interviews with clinicians, reimbursement specialists, supply-chain executives, and patient advocacy representatives to capture practical insights on care patterns, access barriers, and real-world treatment preferences. These conversations were designed to illuminate operational nuances and to validate hypothesis-driven analytic frameworks.

Secondary research complemented primary findings by consolidating peer-reviewed literature, regulatory guidance, clinical practice recommendations, and publicly available health-system reports. Data triangulation techniques were applied to reconcile differing source perspectives and to strengthen the reliability of interpretation. Analytic rigor was maintained through iterative peer review, methodological transparency, and quality checks on sourcing and interpretation. Where applicable, sensitivity analysis and scenario planning were used to test the robustness of strategic implications, supporting more resilient recommendations for stakeholders across clinical, commercial, and policy domains.

Synthesis of clinical, commercial, and operational imperatives that leaders must align to translate therapeutic progress into durable patient and system-level value

In sum, the ankylosing spondylitis landscape is characterized by clinical innovation, evolving care models, and operational pressures that together create both opportunity and complexity for stakeholders. Therapeutic diversification, enhanced diagnostics, and digital health integration are reshaping how patients are diagnosed and managed, while payer and procurement dynamics necessitate more sophisticated value communication and adaptive supply strategies. The interplay between administration routes, patient demographics, and care settings further refines where and how treatments will achieve meaningful clinical impact.

Strategic success will depend on aligning evidence-generation efforts with pragmatic commercialization tactics, investing in flexible manufacturing and distribution, and building partnerships that extend beyond traditional product-centric models. By focusing on patient outcomes, regional particularities, and resilient operational design, organizations can navigate policy shifts and adoption hurdles while delivering improved care. The conclusion emphasizes that deliberate, integrated approaches will be required to translate scientific progress into lasting patient benefit and sustainable commercial performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ankylosing Spondylitis Market, by Administration Route

  • 8.1. Injectable
    • 8.1.1. Intravenous Infusion
    • 8.1.2. Subcutaneous Injection
  • 8.2. Intravenous
  • 8.3. Oral
    • 8.3.1. Capsules
    • 8.3.2. Tablets

9. Ankylosing Spondylitis Market, by Patient Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Ankylosing Spondylitis Market, by End User

  • 10.1. Homecare Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Ankylosing Spondylitis Market, by Route Of Administration

  • 11.1. Injectable
    • 11.1.1. Intravenous Infusion
    • 11.1.2. Subcutaneous Injection
  • 11.2. Oral
    • 11.2.1. Solutions
    • 11.2.2. Tablets
  • 11.3. Topical
    • 11.3.1. Creams
    • 11.3.2. Gels

12. Ankylosing Spondylitis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Ankylosing Spondylitis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Ankylosing Spondylitis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Ankylosing Spondylitis Market

16. China Ankylosing Spondylitis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. Biothera Pharmaceuticals, Inc.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. Celgene Corporation
  • 17.11. Celltrion Healthcare Co.,Ltd.
  • 17.12. Eisai Co., Ltd
  • 17.13. Eli Lilly and Company
  • 17.14. Gilead Sciences, Inc.
  • 17.15. GlaxoSmithKline PLC
  • 17.16. Hetero Drugs Limited
  • 17.17. Johnson & Johnson Services Inc.
  • 17.18. Merck & Co. Inc.
  • 17.19. Mylab Discovery Solutions Pvt. Ltd.
  • 17.20. Novartis AG
  • 17.21. Pfizer, Inc.
  • 17.22. Reliance Life Sciences
  • 17.23. Samsung Bioepis Co., Ltd.
  • 17.24. Sandoz International GmbH
  • 17.25. Shanghai Pharmaceuticals Holding Co., Ltd.
  • 17.26. Takeda Pharmaceutical Company Limited
  • 17.27. Trinity Biotech PLC
  • 17.28. UCB, Inc.
  • 17.29. Xian Janssen Pharmaceutical Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 208. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 213. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 218. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)